新闻

Altamira Medica Ltd. has agreed with its partner Nuance Pharma to extend the territory covered by their exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia.

Verona Pharma plc (Nasdaq: VRNA) announces the US Food and Drug Administration (FDA) approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD

Verona Pharma plc (Nasdaq: VRNA) announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of

Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis

Verona Pharma plc (Nasdaq: VRNA) announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of COPD

Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control.

Altamira Therapeutics Ltd. announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)

Altamira Therapeutics Ltd. provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR)